stars 1 stars 2 stars 3

The overall aim of PRECISION-Panc is to speed up scientific discovery in order to improve the survival rates of patients with pancreatic cancer. PRECISION-Panc serves as a “portal” for patients with known or suspected pancreatic cancer to be accrued through multiple centres in the UK, with the option of being subsequently enrolled into PRIMUS (Pancreatic canceR Individualised Multi-arm Umbrella Study) examining different treatment regimens and/or biomarker development. Eligible patients will undergo tumour biopsy and blood collection prospectively for molecular profiling at the Glasgow Precision Oncology Laboratory, and the results may be used to inform enrolment to PRIMUS studies. Our primary objective is to establish a mechanism and framework to recruit and screen patients with pancreatic cancer to perform molecular profiling, evaluation of circulating biomarkers, and enable enrolment into PRECISION-Panc PRIMUS studies.

Precision-Panc Questions

The Precision-Panc annual revenue was $6.8 million in 2026.

The NAICS codes for Precision-Panc are [622, 62].

The SIC codes for Precision-Panc are [80, 806].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users